Xponance Inc. Buys 1,083 Shares of Hologic, Inc. (NASDAQ:HOLX)

Xponance Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 3.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 34,027 shares of the medical equipment provider’s stock after acquiring an additional 1,083 shares during the period. Xponance Inc.’s holdings in Hologic were worth $2,453,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its stake in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after acquiring an additional 2,174,093 shares during the last quarter. Boston Partners grew its holdings in Hologic by 81.0% during the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Nordea Investment Management AB grew its holdings in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the period. Raymond James Financial Inc. acquired a new position in Hologic during the fourth quarter worth approximately $27,007,000. Finally, Swedbank AB lifted its position in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after buying an additional 306,562 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HOLX. Raymond James restated an “outperform” rating and issued a $90.00 price target (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Citigroup decreased their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Morgan Stanley reduced their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Performance

HOLX opened at $61.47 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67. The firm has a market cap of $13.79 billion, a P/E ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business’s fifty day moving average is $66.06 and its 200-day moving average is $74.05.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.